Iztok Grabnar

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 19

Top Venues

Medicina (Kaunas, Lithuania)

Pharmaceuticals (Basel, Switzerland)

Acta pharmaceutica (Zagreb, Croatia)

Drugs in R&D

University of Ljubljana (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

University of Ljubljana Oct 01 1996 - Jul 28 2000

Slovenia

PHD :: Faculty of Pharmacy

Publications

Boštjan Martinc, Iztok Grabnar, Daniela Milosheska, Bogdan Lorber, Tomaž Vovk
A Cross-Sectional Study Comparing Oxidative Stress in Patients with Epilepsy Treated with Old and New Generation Antiseizure Medications. Medicina (Kaunas, Lithuania) 60 (8) (2024)
Daniela Milosheska, Robert Roškar, Tomaž Vovk, Bogdan Lorber, Iztok Grabnar, Jurij Trontelj
An LC-MS/MS Method for Quantification of Lamotrigine and Its Main Metabolite in Dried Blood Spots. Pharmaceuticals (Basel, Switzerland) 17 (4) (2024)
Matej Dobravc Verbič, Iztok Grabnar, Miran Brvar
Association between Prescribing and Intoxication Rates for Selected Psychotropic Drugs: A Longitudinal Observational Study. Pharmaceuticals (Basel, Switzerland) 17 (1) (2024)
Matej Dobravc Verbič, Iztok Grabnar, Miran Brvar
Association between Prescribing and Intoxication Rates for Selected Psychotropic Drugs: A Longitudinal Observational Study. Pharmaceuticals (Basel, Switzerland) 17 (1) (2024)
Matej Dobravc Verbič, Iztok Grabnar, Miran Brvar
Association between Prescribing and Intoxication Rates for Selected Psychotropic Drugs: A Longitudinal Observational Study. Pharmaceuticals (Basel, Switzerland) 17 (1) (2024)
Daniela Milosheska, Robert Roškar, Tomaž Vovk, Bogdan Lorber, Iztok Grabnar, Jurij Trontelj
An LC-MS/MS Method for Quantification of Lamotrigine and Its Main Metabolite in Dried Blood Spots. Pharmaceuticals (Basel, Switzerland) 17 (4) (2024)
Katja Čvan Trobec, Iztok Grabnar, Jurij Trontelj, Mitja Lainscak, Mojca Kerec Kos
Population pharmacokinetics of ramipril in patients with chronic heart failure: A real-world longitudinal study. Acta pharmaceutica (Zagreb, Croatia) 74 (2) (2024)
Cvetka Bačar Bole, Katja Nagode, Mitja Pišlar, Aleš Mrhar, Iztok Grabnar, Tomaž Vovk
Potential Drug-Drug Interactions among Patients with Schizophrenia Spectrum Disorders: Prevalence, Association with Risk Factors, and Replicate Analysis in 2021. Medicina (Kaunas, Lithuania) 59 (2) (2023)
Dejan Krajcar, Iztok Grabnar, Rebeka Jereb, Igor Legen, Jerneja Opara
Predictive Potential of BCS and Pharmacokinetic Parameters on Study Outcome: Analysis of 198 In Vivo Bioequivalence Studies. European journal of drug metabolism and pharmacokinetics (2023)
Cvetka Bačar Bole, Katja Nagode, Mitja Pišlar, Aleš Mrhar, Iztok Grabnar, Tomaž Vovk
Potential Drug-Drug Interactions among Patients with Schizophrenia Spectrum Disorders: Prevalence, Association with Risk Factors, and Replicate Analysis in 2021. Medicina (Kaunas, Lithuania) 59 (2) (2023)
Dejan Krajcar, Rebeka Jereb, Igor Legen, Jerneja Opara, Iztok Grabnar
Predictive Potential of Acido-Basic Properties, Solubility and Food on Bioequivalence Study Outcome: Analysis of 128 Studies. Drugs in R&D (2023)
Cvetka Bačar Bole, Katja Nagode, Mitja Pišlar, Aleš Mrhar, Iztok Grabnar, Tomaž Vovk
Potential Drug-Drug Interactions among Patients with Schizophrenia Spectrum Disorders: Prevalence, Association with Risk Factors, and Replicate Analysis in 2021. Medicina (Kaunas, Lithuania) 59 (2) (2023)
Mateja Črček, Iztok Grabnar, Jurij Aguiar Zdovc, Štefan Grosek, Mojca Kerec Kos
External validation of population pharmacokinetic models of gentamicin in paediatric population from preterm newborns to adolescents. Acta pharmaceutica (Zagreb, Croatia) 73 (2) (2023)
Cvetka Bačar Bole, Katja Nagode, Mitja Pišlar, Aleš Mrhar, Iztok Grabnar, Tomaž Vovk
Potential Drug-Drug Interactions among Patients with Schizophrenia Spectrum Disorders: Prevalence, Association with Risk Factors, and Replicate Analysis in 2021. Medicina (Kaunas, Lithuania) 59 (2) (2023)
Cvetka Bačar Bole, Katja Nagode, Mitja Pišlar, Aleš Mrhar, Iztok Grabnar, Tomaž Vovk
Potential Drug-Drug Interactions among Patients with Schizophrenia Spectrum Disorders: Prevalence, Association with Risk Factors, and Replicate Analysis in 2021. Medicina (Kaunas, Lithuania) 59 (2) (2023)
Jurij Aguiar Zdovc, Mihaela Vaupotič, Gregor Marolt, Lea Knez, Renata Režonja Kukec, Tanja Čufer, Tomaž Vovk, Iztok Grabnar
Population pharmacokinetics of cisplatin in small cell lung cancer patients guided with informative priors. Cancer chemotherapy and pharmacology 90 (4) (2022)
Jurij Aguiar Zdovc, Jurij Hanžel, Tina Kurent, Nejc Sever, Matic Koželj, Nataša Smrekar, Gregor Novak, Borut Štabuc, Erwin Dreesen, Debby Thomas, Tomaž Vovk, Barbara Ostanek, David Drobne, Iztok Grabnar
Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model. Pharmaceutics 13 (10) (2021)
Panagiotis-Dimitrios Mingas, Jurij Aguiar Zdovc, Iztok Grabnar, Tomaž Vovk
The Evolving Role of Microsampling in Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Diseases. Molecules (Basel, Switzerland) 26 (6) (2021)
Jurij Zdovc, Maja Petre, Mitja Pišlar, Katja Repnik, Aleš Mrhar, Matjaž Vogrin, Uroš Potočnik, Iztok Grabnar
Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study. European journal of clinical pharmacology 75 (6) (2019)

Iztok Grabnar.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Iztok Grabnar